Last updated: 9 June 2023 at 4:56pm EST

Parag Shah Net Worth




The estimated Net Worth of Parag Suresh Shah is at least $1.02 Tisíc dollars as of 9 December 2022. Parag Shah owns over 25,500 units of Bellerophon Therapeutics Inc stock worth over $1,020 and over the last 8 years he sold BLPH stock worth over $0. In addition, he makes $0 as Vice President - Business Operations at Bellerophon Therapeutics Inc.

Parag Shah BLPH stock SEC Form 4 insiders trading

Parag has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 25,500 units of BLPH stock worth $1,020 on 9 December 2022.

The largest trade he's ever made was exercising 25,500 units of Bellerophon Therapeutics Inc stock on 9 December 2022 worth over $1,020. On average, Parag trades about 1,594 units every 0 days since 2016. As of 9 December 2022 he still owns at least 25,500 units of Bellerophon Therapeutics Inc stock.

You can see the complete history of Parag Shah stock trades at the bottom of the page.





Parag Shah biography

Dr. Parag Shah Ph.D. serves as Vice President - Business Operations of the Company. He is with responsibilities for Project Management, Supply Distribution, Pre-Clinical and Business Development activities. Prior to joining Bellerophon, Dr. Shah was Principal Scientist at Pfizer from 2004 through 2010 where he was responsible for leading multiple parenteral and liquid formulation development teams. In addition, Dr. Shah was a member of multiple Limited Duration Teams including serving as Pfizer’s Team Lead for the Nanoparticle Network responsible for internal and external evaluation of nanoparticle technologies. Dr. Shah joined Ikaria as Parenteral Development Lead in 2010 and assumed additional responsibilities in 2012 as Director, Pharmaceutical Science, covering both Pharmaceutical Development and Clinical Supply Management. Dr. Shah received his Bachelor’s degree from Carnegie Mellon and his Ph.D. in Chemical Engineering from The University of Texas at Austin.



How old is Parag Shah?

Parag Shah is 43, he's been the Vice President - Business Operations of Bellerophon Therapeutics Inc since 2016. There are 14 older and 3 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.

What's Parag Shah's mailing address?

Parag's mailing address filed with the SEC is 20 INDEPENDENCE BLVD., SUITE 402, WARREN, NJ, 07059.

Insiders trading at Bellerophon Therapeutics Inc

Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein a Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.



What does Bellerophon Therapeutics Inc do?

bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.



What does Bellerophon Therapeutics Inc's logo look like?

Bellerophon Therapeutics Inc logo

Complete history of Parag Shah stock trades at Bellerophon Therapeutics Inc

Datum
#
Společnost
Osoba
Trans.
Transakce
Počet akcií Cena za akcii Celková cena Počet akcií po Zdroj
9 Dec 2022 Parag Suresh Shah
VP of Business Operations
Využití opce 25,500 $0.97 $24,735
9 Dec 2022
25,500


Bellerophon Therapeutics Inc executives and stock owners

Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include: